191 related articles for article (PubMed ID: 15574762)
1. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy.
Bertucci F; Finetti P; Rougemont J; Charafe-Jauffret E; Nasser V; Loriod B; Camerlo J; Tagett R; Tarpin C; Houvenaeghel G; Nguyen C; Maraninchi D; Jacquemier J; Houlgatte R; Birnbaum D; Viens P
Cancer Res; 2004 Dec; 64(23):8558-65. PubMed ID: 15574762
[TBL] [Abstract][Full Text] [Related]
2. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
Van Laere S; Beissbarth T; Van der Auwera I; Van den Eynden G; Trinh XB; Elst H; Van Hummelen P; van Dam P; Van Marck E; Vermeulen P; Dirix L
Clin Cancer Res; 2008 Nov; 14(22):7452-60. PubMed ID: 19010862
[TBL] [Abstract][Full Text] [Related]
3. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis.
Van Laere S; Van der Auwera I; Van den Eynden GG; Fox SB; Bianchi F; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Breast Cancer Res Treat; 2005 Oct; 93(3):237-46. PubMed ID: 16172796
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; Elst HJ; Weyler J; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3249-56. PubMed ID: 16740744
[TBL] [Abstract][Full Text] [Related]
5. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.
Van Laere SJ; Van den Eynden GG; Van der Auwera I; Vandenberghe M; van Dam P; Van Marck EA; van Golen KL; Vermeulen PB; Dirix LY
Breast Cancer Res Treat; 2006 Feb; 95(3):243-55. PubMed ID: 16261404
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of inflammatory breast cancer.
Bertucci F; Finetti P; Birnbaum D; Viens P
Cancer; 2010 Jun; 116(11 Suppl):2783-93. PubMed ID: 20503410
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
[TBL] [Abstract][Full Text] [Related]
8. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic molecular classification of breast cancers based on gene expression profiling].
Feng YM; Li XQ; Sun BC; Gao XC; Gu L; Niu Y; Hao XS
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):900-6. PubMed ID: 17533740
[TBL] [Abstract][Full Text] [Related]
11. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer.
Folgueira MA; Carraro DM; Brentani H; Patrão DF; Barbosa EM; Netto MM; Caldeira JR; Katayama ML; Soares FA; Oliveira CT; Reis LF; Kaiano JH; Camargo LP; Vêncio RZ; Snitcovsky IM; Makdissi FB; e Silva PJ; Góes JC; Brentani MM
Clin Cancer Res; 2005 Oct; 11(20):7434-43. PubMed ID: 16243817
[TBL] [Abstract][Full Text] [Related]
13. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue.
Mina L; Soule SE; Badve S; Baehner FL; Baker J; Cronin M; Watson D; Liu ML; Sledge GW; Shak S; Miller KD
Breast Cancer Res Treat; 2007 Jun; 103(2):197-208. PubMed ID: 17039265
[TBL] [Abstract][Full Text] [Related]
14. cDNA microarray analysis of inflammatory breast cancer signatures.
Laere SJ; Vermeulen PB; Dirix LY
Methods Mol Biol; 2009; 512():71-98. PubMed ID: 19347274
[TBL] [Abstract][Full Text] [Related]
15. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
16. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer.
Arango D; Laiho P; Kokko A; Alhopuro P; Sammalkorpi H; Salovaara R; Nicorici D; Hautaniemi S; Alazzouzi H; Mecklin JP; Järvinen H; Hemminki A; Astola J; Schwartz S; Aaltonen LA
Gastroenterology; 2005 Sep; 129(3):874-84. PubMed ID: 16143127
[TBL] [Abstract][Full Text] [Related]
17. A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study.
Chanrion M; Fontaine H; Rodriguez C; Negre V; Bibeau F; Theillet C; Hénaut A; Darbon JM
BMC Cancer; 2007 Mar; 7():39. PubMed ID: 17338809
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Hess KR; Anderson K; Symmans WF; Valero V; Ibrahim N; Mejia JA; Booser D; Theriault RL; Buzdar AU; Dempsey PJ; Rouzier R; Sneige N; Ross JS; Vidaurre T; Gómez HL; Hortobagyi GN; Pusztai L
J Clin Oncol; 2006 Sep; 24(26):4236-44. PubMed ID: 16896004
[TBL] [Abstract][Full Text] [Related]
19. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.
Nguyen DM; Sam K; Tsimelzon A; Li X; Wong H; Mohsin S; Clark GM; Hilsenbeck SG; Elledge RM; Allred DC; O'Connell P; Chang JC
Clin Cancer Res; 2006 Sep; 12(17):5047-54. PubMed ID: 16951220
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.
Bertucci F; Finetti P; Cervera N; Charafe-Jauffret E; Mamessier E; Adélaïde J; Debono S; Houvenaeghel G; Maraninchi D; Viens P; Charpin C; Jacquemier J; Birnbaum D
Cancer Res; 2006 May; 66(9):4636-44. PubMed ID: 16651414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
